Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison

Conclusion: In the present study, we found that erenumab had a more favorable efficacy profile than rimegepant in reducing MMDs at month 1 and month 3 for migraine prevention. These results may help with decision-making in clinical practice and can be further validated in future clinical trials or real-world studies.PMID:38174577 | DOI:10.57264/cer-2023-0122

Source: Journal of Comparative Effectiveness Research - January 4, 2024 Category: General Medicine Authors: Ronan Mahon Santosh Tiwari Mirja Koch Matias Ferraris Keith A Betts Yan Wang Sophie Gao Pascal Proot Source Type: research